Enrollment and Outcomes

Slides:

Advertisements

Similar presentations

Sibbing D, et al. J Am Coll Cardiol 2009;53:

Advertisements

Montalescot G, et al. Lancet 2009;373: Trial profile Montalescot G, et al. Lancet 2009;373:

1 MT vs CT: 28 day survival Number at risk CT MT day % Surviving Monotherapy.

COURAGE: Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation Purpose To compare the efficacy of optimal medical therapy (OMT)

Demographic Characteristics of the Study Population - Part I Jenny N.Poynter et al N Engl J Med 2005;352:

Solomon Tesfaye et al N Engl J Med 2005;352: Comparison of Baseline Data in 1819 Patients According to Whether There Was an Assessment for Neuropathy.

Enrollment and Outcomes Fan Fan Hou, et al. N Engl J Med 2006;354:

Enrollment, Randomization, and Follow-up of Study Participants ADVANCE Collaborative Group. N Engl J Med 2008;358:

The ILLUMINATE Study: Enrollment and Outcomes Philip Barter, et al. N Engl J Med 2007;357:

Charlotte Kragelund et al N Engl J Med 2005;352: Baseline Clinical Characteristics According to Quartiles of NT-pro-BNP.

Baseline Characteristics of the Patients* - Part I The ONTARGET Investigators. N Engl J Med 2008 [Epub on Mar 31]

Trial profile Mann JF et al. Lancet 2008;372:

Enrollment and Outcomes Duckworth W, et al. N Engl J Med 2009;360:

Trial profile SAS denotes the Simvastatin in Aortic Stenosis Study

Baseline Characteristics of the Patients Part I

Baseline Characteristics of Women and Men in Whom Coronary Heart Disease Developed during Follow-up and Matched Controls - A Jennifer K. Pai et al. N.

Effects of High Density Lipoprotein Raising Therapies on Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus, with or without Renal Impairment:

Kaplan-Meier survival curves comparing survival between both time periods according to management strategy. Survival in patients with infective endocarditis.

TNT Study: Baseline Characteristics of the Patients

Trial profile John A Dormandy et al. Lancet 2005;366:

Study Design Ketil Lunde, et al. N Engl J Med 2006;355:

Jun M, et al. Lancet 2010 Epub May 10

Fellström BC, et al. N Engl J Med 2009;360:1455-7

A: Kaplan-Meier estimate of time to first LLA

Kaplan-Meier curves comparing: (A) overall survival for patients treated on trial compared to those outside of a trial; (B) progression-free survival for.

Risk for BMI outcome (%)

Baseline Characteristics, Values at 24-Month Follow-up, and Changes from Baseline* - Part I John J.P. Kastelein, et al. N Engl J Med 2007;356: online.

Inclusion Criteria for Patients with Multiple Atherothrombotic Risk Factors and for Those with Established Cardiovascular Disease Deepak L.Bhatt, et al,

Baseline Characteristics of the Subjects

Characteristics of the Patients at Baseline*

(A) Kaplan-Meier curve showing AF-free survival after a single procedure for patients grouped according to use of CT integration. (A) Kaplan-Meier curve.

Baseline Characteristics of the Patients and Use of Concomitant Medications – Part I Kaare Harald Bønaa, et al. N Engl J Med 2006;354:

A.V. Khera et al. N Engl J Med 2011;364:127-35

Baseline Characteristics of the Study Participants

Baseline Characteristics, Blood Pressures, and Laboratory Values

Effects of Pay-for-Performance on the Quality of Primary Care in England Mean Scores for Clinical Quality at the Practice Level for Aspects of Care for.

Jeffrey S. Berger, et al. Circ Cardiovasc Qual Outcomes 2009;2:78-87

Patient Disposition James A. de Lemos et al. JAMA 2004; 292:

Participation in Japanese Primary Prevention of Atherosclerosis With Aspirin for Diabetes (JPAD) Trial Hisao Ogawa et al. JAMA 2008;300:

Receiver operating characteristic curves for the association of primary outcome using each clinical risk score and each clinical risk score adjusted for.

Baseline Characteristics of Elderly Participants in the Cardiovascular Health Study,According to Quintiles of Cystatin C Michael G.Shlipak et al N Engl.

Kaplan-Meier survival curve for unloader brace—Kaplan-Meier survival analysis demonstrated rapid conversion to TKR for the first 12 months, which then.

Kaplan-Meier survival curves for the development of diabetes by quartiles of baseline pedometer steps. Kaplan-Meier survival curves for the development.

Kaplan-Meier curves showing the time in months to the first inappropriate shock from the start of remote monitoring in primary and secondary prevention.

Baseline Characteristics of the Patients – Part I

RECORD Study: Enrollment and Outcomes

The ACCORD Study Group. NEJM 2010; Epub March 14

Kaplan-Meier Curves for the Percentages of Subjects with Microalbuminuria during Treatment with Trandolapril plus Verapamil or Placebo Piero Ruggenenti.

Baseline Characteristics of the Patients - Part I

Enrollment and Outcomes

Comparison of Baseline Characteristics by Primary End Point

Kaplan-Meier survival curves for non-fatal stroke or mortality based on IMRS categories among (A) women (p-trend

Baseline Clinical Characteristics of All Patients and Patients Grouped by Statin Therapy - Part I H. Fukuta et al. Circulation 2005;112:

Baseline characteristics of study population

Representative Light Micrographs of Kidney Sections Illustrating the Histologic Scoring Criteria Giuseppe Remuzzi, et al, N Engl J Med 2006;3354:

The Kaplan-Meier curves display the time to event for the primary outcome (A) and total mortality (B) during follow-up from randomization until the end.

Kaplan-Meier survival curve for CVD mortality among physically active and inactive type 2 diabetic patients stratified by baseline hs-CRP levels. Kaplan-Meier.

Kaplan-Meier survival curve for all catheterisations.

Kaplan-Meier survival curves of the IMRS association with non-fatal stroke/mortality (stroke-free survival) in women with AF, stratified by CHA2DS2-VASc.

Kaplan-Meier estimates of all-cause mortality at 30 days.

• Kaplan-Meier analyses of (A) time-to-recurrence (TTR) for the subgroup of patients with high-risk melanoma who had relapsed (n=82), (B) recurrence-free.

Kaplan-Meier survival (renal event-free) curves during follow-up by tertiles of plasma copeptin. Kaplan-Meier survival (renal event-free) curves during.

Survival of subjects listed for heart transplantation with different spirometric ventilatory patterns. Survival of subjects listed for heart transplantation.

Survival of subjects listed for heart transplantation with and without spirometry. Survival of subjects listed for heart transplantation with and without.

Overall and recurrence-free survival.

Kaplan-Meier estimates for survival in metastatic disease for the whole patient cohort (A) and in patients with or without history of adjuvant trastuzumab.

Kaplan-Meier curve of the primary outcome in patients prescribed ACE inhibitor (ACEI) and angiotensin receptor blocker (ARB). Kaplan-Meier curve of the.

Avasare et al. Am J Nephrol 2017;45:99-106 (DOI: / )

Kaplan-Meier curves showing the probability of symptom-free survival according to the rate of heart rate rise during exercise testing in (A) for the whole.

Kaplan-Meier (K-M) curves of progression-free survival (PFS) in 54 patients with metastatic gastric cancer treated with RAD001. Kaplan-Meier (K-M) curves.

Presentation transcript:

Enrollment and Outcomes Boden WE et al. N Engl J Med 2007;356:1503-1516

Baseline Clinical and Angiographic Characteristics - Part I Boden WE et al. N Engl J Med 2007;356:1503-1516

Baseline Clinical and Angiographic Characteristics - Part II Boden WE et al. N Engl J Med 2007;356:1503-1516

Clinical Status, Risk and Lifestyle Factors, and Use of Medication Boden WE et al. N Engl J Med 2007;356:1503-1516

Primary and Secondary Outcomes Boden WE et al. N Engl J Med 2007;356:1503-1516

Kaplan-Meier Survival Curves Boden WE et al. N Engl J Med 2007;356:1503-1516

Subgroup Analyses Boden WE et al. N Engl J Med 2007;356:1503-1516